Simiso Sokhela to HIV-1
This is a "connection" page, showing publications Simiso Sokhela has written about HIV-1.
Connection Strength
0,676
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,117
-
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
Score: 0,105
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,100
-
Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. AIDS. 2020 02 01; 34(2):321-324.
Score: 0,095
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,092
-
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
Score: 0,091
-
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS. 2025 Mar 15; 39(4):448-456.
Score: 0,033
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,031
-
Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010 Mar 30; 10:83.
Score: 0,012